Role of TET enzymes in DNA methylation, development, and cancer

Genes and Development

Volumn 30, Issue 7, 2016, Pages 733-750

  Rasmussen, Kasper Dindler ^a,b   Helin, Kristian ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

DNA demethylation; DNA methylation; Hematopoiesis; Hydroxymethyl cytosine; Leukemia; TET

Indexed keywords

5 CARBOXYLCYTOSINE; 5 FORMYLCYTOSINE; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; CYTOSINE DERIVATIVE; DNA; ENZYME; TEN ELEVEN TRANSLOCATION ENZYME; UNCLASSIFIED DRUG; CYTOSINE; DIOXYGENASE; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

CARCINOGENESIS; DNA METHYLATION; DNA TRANSCRIPTION; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; METABOLIC REGULATION; NEOPLASM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ANIMALS; CYTOSINE; DIOXYGENASES; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; PROTO-ONCOGENE PROTEINS;

EID: 84962339365     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.276568.115     Document Type: Review

References (159)

1. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, LaFave LM, et al. 2013. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210: 2641–2659.
2. An J, González-Avalos E, Chawla A, Jeong M, López-Moyado IF, Li W, Goodell MA, Chavez L, Ko M, Rao A. 2015. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun 6: 10071.
3. Bachman M, Uribe-Lewis S, Yang X, Williams M, Murrell A, Balasubramanian S. 2014. 5-hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem 6: 1049–1055.
4. Bachman M, Uribe-Lewis S, Yang X, Burgess HE, Iurlaro M, Reik W, Murrell A, Balasubramanian S. 2015. 5-formylcytosine can be a stable DNA modification in mammals. Nat Chem Biol 11: 555–557.
5. Baylin SB, Jones PA. 2011. A decade of exploring the cancer epigenome— biological and translational implications. Nat Rev Cancer 11: 726–734.
6. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia- Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, et al. 2011. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496–2506.
7. Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, et al. 2014. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124: 2705–2712.
8. Blaschke K, Ebata KT, Karimi MM, Zepeda-Martínez JA, Goyal P, Mahapatra S, Tam A, Laird DJ, Hirst M, Rao A, et al. 2013. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500: 222–226.
9. Boulard M, Edwards JR, Bestor TH. 2015. FBXL10 protects Polycomb- bound genes from hypermethylation. Nat Genet 47: 479–485.
10. Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, et al. 2011. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 118: 3824–3831.
11. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, et al. 2012. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44: 1179–1181.
12. Cancer Genome Atlas Research Network. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059–2074.
13. Chan SM, Majeti R. 2013. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 98: 648–657.
14. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. 2003. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 23: 5594–5605.
15. Chen Q, Chen Y, Bian C, Fujiki R, Yu X. 2013. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493: 561–564.
16. Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, et al. 2015. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood 125: 327–335.
17. Cheng J, Guo S, Chen S, Mastriano SJ, Liu C, D’Alessio AC, Hysolli E, Guo Y, Yao H, Megyola CM, et al. 2013. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep 5: 471–481.
18. Chuang K-H, Whitney-Miller CL, Chu C-Y, Zhou Z, Dokus MK, Schmit S, Barry CT. 2015. MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors. Hepatology 62: 466–480.
19. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, Bushweller JH. 2010. Structure of the MLL CXXC domain–DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 17: 62–68.
20. Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, et al. 2015. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol 16: 653–662.
21. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, et al. 2011. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146: 67–79.
22. Costa Y, Ding J, Theunissen TW, Faiola F, Hore TA, Shliaha PV, Fidalgo M, Saunders A, Lawrence M, Dietmann S, et al. 2013. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 495: 370–374.
23. Dawlaty MM, Ganz K, Powell BE, Hu Y-C, Markoulaki S, Cheng AW, Gao Q, Kim J, Choi S-W, Page DC, et al. 2011. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Stem Cell 9: 166–175.
24. Dawlaty MM, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng AW, Gao Q, Powell BE, Li Z, Xu M, et al. 2013. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell 24: 310–323.
25. Dawlaty MM, Breiling A, Le T, Barrasa MI, Raddatz G, Gao Q, Powell BE, Cheng AW, Faull KF, Lyko F, et al. 2014. Loss of Tet enzymes compromises proper differentiation of embryonic stem cells. Dev Cell 29: 102–111.
26. Delhommeau F, Dupont S, Valle Della V, James C, Trannoy S, Massé A, Kosmider O, Le Couédic J-P, Robert F, Alberdi A, et al. 2009. Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289–2301.
27. Deplus R, Delatte B, Schwinn MK, Defrance M, Méndez J, Murphy N, Dawson MA, Volkmar M, Putmans P, Calonne E, et al. 2013. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J 32: 645–655.
28. De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, et al. 2014. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One 9: e96209.
29. Doege CA, Inoue K, Yamashita T, Rhee DB, Travis S, Fujita R, Guarnieri P, Bhagat G, Vanti WB, Shih A, et al. 2012. Earlystage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 488: 652–655.
30. Feng J, Shao N, Szulwach KE, Vialou V, Huynh J, Zhong C, Le T, Ferguson D, Cahill ME, Li Y, et al. 2015. Role of Tet1 and 5- hydroxymethylcytosine in cocaine action. Nat Neurosci 18: 536–544.
31. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553–567.
32. Frauer C, Hoffmann T, Bultmann S, Casa V, Cardoso MC, Antes I, Leonhardt H. 2011. Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain. PLoS One 6: e21306.
33. Fu X, Jin L, Wang X, Luo A, Hu J, Zheng X, Tsark WM, Riggs AD, Ku HT, Huang W. 2013. MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proc Natl Acad Sci 110: 17892–17897.
34. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, et al. 2014. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371: 2477–2487.
35. Globisch D, Münzel M, Müller M, Michalakis S, Wagner M, Koch S, Brückl T, Biel M, Carell T. 2010. Tissue distribution of 5- hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 5: e15367.
36. Gu T-P, Guo F, Yang H, Wu H-P, Xu G-F, Liu W, Xie Z-G, Shi L, He X, Jin S-G, et al. 2011. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 477: 606–610.
37. Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE, Gomez V, Hergovich A, Tirabosco R, Fernanda Amary M, et al. 2013. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun 4: 2166.
38. Guo X, Wang L, Li J, Ding Z, Xiao J, Yin X, He S, Shi P, Dong L, Li G, et al. 2015. Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature 517: 640–644.
39. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, et al. 2014. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28: 241–247.
40. Hahn MA, Qiu R, Wu X, Li AX, Zhang H, Wang J, Jui J, Jin S-G, Jiang Y, Pfeifer GP, et al. 2013. Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis. Cell Rep 3: 291–300.
41. Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, Zhang X, Cheng X. 2012. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res 40: 4841–4849.
42. Hashimoto H, Olanrewaju YO, Zheng Y, Wilson GG, Zhang X, Cheng X. 2014a. Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence. Genes Dev 28: 2304–2313.
43. Hashimoto H, Pais JE, Zhang X, Saleh L, Fu Z-Q, Dai N, Corrêa IR, Zheng Y, Cheng X. 2014b. Structure of a Naegleria Tetlike dioxygenase in complex with 5-methylcytosine DNA. Nature 506: 391–395.
44. Hashimoto H, Pais JE, Dai N, Corrêa IR, Zhang X, Zheng Y, Cheng X. 2015. Structure of Naegleria Tet-like dioxygenase (NgTet1) in complexes with a reaction intermediate 5-hydroxymethylcytosine DNA. Nucleic Acids Res 43: 10713–10721.
45. Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, Joergens JE, Shih AH, et al. 2016. Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. J Exp Med 213: 25–34.
46. He Y-F, Li B-Z, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al. 2011. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303–1307.
47. Hill PWS, Amouroux R, Hajkova P. 2014. DNA demethylation, Tet proteins and 5-hydroxymethylcytosine in epigenetic reprogramming: an emerging complex story. Genomics 104: 324–333.
48. Hon GC, Rajagopal N, Shen Y, McCleary DF, Yue F, Dang MD, Ren B. 2013. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat Genet 45: 1198–1206.
49. Hon GC, Song C-X, Du T, Jin F, Selvaraj S, Lee AY, Yen C-A, Ye Z, Mao S-Q, Wang B-A, et al. 2014. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol Cell 56: 286–297.
50. Hu L, Li Z, Cheng J, Rao Q, Gong W, Liu M, Shi YG, Zhu J, Wang P, Xu Y. 2013. Crystal structure of TET2–DNA complex: insight into TET-mediated 5mC oxidation. Cell 155: 1545–1555.
51. Hu L, Lu J, Cheng J, Rao Q, Li Z, Hou H, Lou Z, Zhang L, Li W, Gong W, et al. 2015. Structural insight into substrate preference for TET-mediated oxidation. Nature 527: 118–122.
52. Ichiyama K, Chen T, Wang X, Yan X, Kim B-S, Tanaka S, Ndiaye-Lobry D, Deng Y, Zou Y, Zheng P, et al. 2015. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 42: 613–626.
53. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. 2011. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300–1303.
54. Ittel A, Jeandidier E, Helias C, Perrusson N, Humbrecht C, Lioure B, Mazurier I, Mayeur-Rousse C, Lavaux A, Thiebault S, et al. 2013. First description of the t(10;11)(q22;q23)/MLL–TET1 translocation in a T-cell lymphoblastic lymphoma, with subsequent lineage switch to acute myelomonocyticmyeloid leukemia. Haematologica 98: e166–e168.
55. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, et al. 2011. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and lowblast count acute myeloid leukemias. Leukemia 25: 1147–1152.
56. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, Adès L, Fenaux P, Platzbecker U, Gagey O, et al. 2013. Clonal architecture of chronic myelomonocytic leukemias. Blood 121: 2186–2198.
57. Iurlaro M, Ficz G, Oxley D, Raiber E-A, Bachman M, Booth MJ, Andrews S, Balasubramanian S, Reik W. 2013. A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol 14: R119.
58. Jain D, Baldi S, Zabel A, Straub T, Becker PB. 2015. Active promoters give rise to false positive ‘phantom peaks’ in ChIPseq experiments. Nucleic Acids Res 43: 6959–6968.
59. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, et al. 2014. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371: 2488–2498.
60. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R. 2012. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 4: 149ra118.
61. Ji D, Lin K, Song J, Wang Y. 2014. Effects of Tet-induced oxidation products of 5-methylcytosine on Dnmt1- andDNMT3a-mediated cytosine methylation. Mol Biosyst 10: 1749–1752.
62. Jin S-G, Kadam S, Pfeifer GP. 2010. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res 38: e125.
63. Jones PA, Liang G. 2009. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 10: 805–811.
64. Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, et al. 2015. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125: 304–315.
65. Kang J, Lienhard M, Pastor WA, Chawla A, Novotny M, Tsagaratou A, Lasken RS, Thompson EC, Surani MA, Koralov SB, et al. 2015. Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis. Proc Natl Acad Sci 112: E4236–E4245.
66. Kellinger MW, Song C-X, Chong J, Lu X-Y, He C, Wang D. 2012. 5-formylcytosine and 5-carboxylcytosine reduce the rate and substrate specificity of RNA polymerase II transcription. Nat Struct Mol Biol 19: 831–833.
67. Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lønning PE, Lillehaug JR, Pendino F. 2011. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Ann Oncol 22: 2208–2215.
68. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al. 2010. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839–843.
69. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB, Rao A. 2011. Teneleven- translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci 108: 14566–14571.
70. Ko M, An J, Bandukwala HS, Chavez L, Aijö T, Pastor WA, Segal MF, Li H, Koh KP, Lähdesmäki H, et al. 2013. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497: 122–126.
71. Ko M, An J, Pastor WA, Koralov SB, Rajewsky K, Rao A. 2015. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev 263: 6–21.
72. Kriaucionis S, Heintz N. 2009. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324: 929–930.
73. Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H, Koike K. 2012. Loss of 5- hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 103: 670–676.
74. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RAP, et al. 2009. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41: 838–842.
75. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M. 2011. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118: 4509–4518.
76. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al. 2012. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150: 1135–1146.
77. Lindahl T, Wood RD. 1999. Quality control by DNA repair. Science 286: 1897–1905.
78. Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y, Dwork AJ, Schultz MD, et al. 2013. Global epigenomic reconfiguration during mammalian brain development. Science 341: 1237905.
79. Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, Yang Z, Wu L, Xia F, Bie P, et al. 2013a. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One 8: e62828.
80. Liu R, Jin Y, Tang WH, Qin L, Zhang X, Tellides G, Hwa J, Yu J, Martin KA. 2013b. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation 128: 2047–2057.
81. Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, et al. 2013. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 210: 301–319.
82. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. 2003. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t (10;11)(q22;q23). Leukemia 17: 637–641.
83. Losman J-A, Kaelin WG. 2013. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27: 836–852.
84. Lu F, Liu Y, Jiang L, Yamaguchi S, Zhang Y. 2014. Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev 28: 2103–2119.
85. Maiti A, Drohat AC. 2011. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem 286: 35334–35338.
86. Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol J-B, Selimoglu- Buet D, Masala E, Allione B, Gioia D, et al. 2015. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 125: 1857–1872.
87. Minor EA, Court BL, Young JI, Wang G. 2013. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenasemediated generation of 5-hydroxymethylcytosine. J Biol Chem 288: 13669–13674.
88. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye- Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, et al. 2011. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11–24.
89. Morita S, Horii T, Kimura M, Ochiya T, Tajima S, Hatada I. 2013. miR-29 represses the activities of DNA methyltransferases and DNA demethylases. Int J Mol Sci 14: 14647–14658.
90. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, et al. 2013. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 210: 2627–2639.
91. Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM. 2012. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat Chem Biol 8: 751–758.
92. Nakagawa T, Lv L, Nakagawa M, Yu Y, Yu C, D’Alessio AC, Nakayama K, Fan H-Y, Chen X, Xiong Y. 2015. CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. Mol Cell 57: 247–260.
93. Neri F, Incarnato D, Krepelova A, Rapelli S, Anselmi F, Parlato C, Medana C, Dal Bello F, Oliviero S. 2015. Single-base resolution analysis of 5-formyl and 5-carboxyl cytosine reveals promoter DNA methylation dynamics. Cell Rep 10: 674–683.
94. Noh K-M, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, et al. 2015. Engineering of a histone-recognition domain in Dnmt3a alters the epigenetic landscape and phenotypic features of mouse ESCs. Mol Cell 59: 89–103.
95. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510–522.
96. Oermann EK, Wu J, Guan K-L, Xiong Y. 2012. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 23: 370–380.
97. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. 2002. LCX,leukemia-associated protein with aCXXCdomain, is fused toMLLin acutemyeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 62: 4075–4080.
98. Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument- Bromage H, Tempst P, Lin S-P, Allis CD, et al. 2007.DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714–717.
99. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, Shirakawa M. 2009. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX–DNMT3– DNMT3L domain. EMBO Rep 10: 1235–1241.
100. Palomero T, Couronné L, Khiabanian H, Kim M-Y, Ambesi- Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, et al. 2014. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46: 166–170.
101. Pastor WA, Pape UJ, Huang Y, Henderson HR, Lister R, Ko M, McLoughlin EM, Brudno Y, Mahapatra S, Kapranov P, et al. 2011. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473: 394–397.
102. Pérez C, Martínez-Calle N, Martín-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, et al. 2012. TET2 mutations are associated with specific 5- methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One 7: e31605.
103. Pfaffeneder T, Hackner B, Truss M, Münzel M, Müller M, Deiml CA, Hagemeier C, Carell T. 2011. The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl 50: 7008–7012.
104. Pfaffeneder T, Spada F, Wagner M, Brandmayr C, Laube SK, Eisen D, Truss M, Steinbacher J, Hackner B, Kotljarova O, et al. 2014. Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. Nat Chem Biol 10: 574–581.
105. Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Massé A, Le Couédic J-P, Pendino F, Carbonne B, et al. 2011. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118: 2551–2555.
106. Putiri EL, Tiedemann RL, Thompson JJ, Liu C, Ho T, Choi J-H, Robertson KD. 2014. Distinct and overlapping control of 5- methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. Genome Biol 15: R81.
107. Quivoron C, Couronné L, Valle Della V, Lopez CK, Plo I, Wagner- Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, et al. 2011. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20: 25–38.
108. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, et al. 2014. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 9: 1841–1855.
109. Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K. 2015. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev 29: 910–922.
110. Rudenko A, Dawlaty MM, Seo J, Cheng AW, Meng J, Le T, Faull KF, Jaenisch R, Tsai L-H. 2013. Tet1 is critical for neuronal activity- regulated gene expression andmemory extinction. Neuron 79: 1109–1122.
111. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, et al. 2014. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46: 171–175.
112. Scourzic L, Mouly E, Bernard OA. 2015. TET proteins and the control of cytosine demethylation in cancer. Genome Med 7: 9.
113. Seisenberger S, Peat JR, Reik W. 2013. Conceptual links between DNA methylation reprogramming in the early embryo and primordial germ cells. Curr Opin Cell Biol 25: 281–288.
114. Sérandour AA, Avner S, Oger F, Bizot M, Percevault F, Lucchetti- Miganeh C, Palierne G, Gheeraert C, Barloy-Hubler F, Péron CL, et al. 2012. Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res 40: 8255–8265.
115. Shen L, Wu H, Diep D, Yamaguchi S, D’Alessio AC, Fung H-L, Zhang K, Zhang Y. 2013. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 153: 692–706.
116. Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, et al. 2012. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 26: 2216–2223.
117. Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony- Debre I, Viale A, Socci N, Sun Y, et al. 2015. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27: 502–515.
118. Song J, Rechkoblit O, Bestor TH, Patel DJ. 2011. Structure of DNMT1–DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 331: 1036–1040.
119. Song C-X, Szulwach KE, Dai Q, Fu Y, Mao S-Q, Lin L, Street C, Li Y, Poidevin M, Wu H, et al. 2013a. Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming. Cell 153: 678–691.
120. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, et al. 2013b. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154: 311–324.
121. Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C, Chandesris MO, Acin Y, Létard S, de Sepulveda P, et al. 2012. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 120: 4846–4849.
122. Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PWTC, Bauer C, Münzel M, Wagner M, Müller M, Khan F, et al. 2013. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152: 1146–1159.
123. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Schöler A, van Nimwegen E, Wirbelauer C, Oakeley EJ, Gaidatzis D, et al. 2011. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480: 490–495.
124. Stroud H, Feng S, Morey Kinney S, Pradhan S, Jacobsen SE. 2011. 5-hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol 12: R54.
125. Szulwach KE, Li X, Li Y, Song C-X, Han JW, Kim S, Namburi S, Hermetz K, Kim JJ, Rudd MK, et al. 2011. Integrating 5- hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet 7: e1002154.
126. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. 2010. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 38: e181.
127. Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. 2014. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res 24: 1421–1432.
128. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930–935.
129. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AWM, Lu C, Ward PS, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479–483.
130. Valinluck V, Sowers LC. 2007. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 67: 946–950.
131. Wang L, Zhang J, Duan J, Gao X, Zhu W, Lu X, Yang L, Zhang J, Li G, Ci W, et al. 2014. Programming and inheritance of parental DNA methylomes in mammals. Cell 157: 979–991.
132. Wang L, Zhou Y, Xu L, Xiao R, Lu X, Chen L, Chong J, Li H, He C, Fu X-D, et al. 2015a. Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature 523: 621–625.
133. Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, et al. 2015b. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell 57: 662–673.
134. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, et al. 2012. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26: 934–942.
135. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PAC, Rappsilber J, Helin K. 2011. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473: 343–348.
136. Williams K, Christensen J, Helin K. 2012.DNAmethylation: TET proteins—guardians of CpG islands? EMBO Rep 13: 28–35.
137. Wu H, Zhang Y. 2014. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156: 45–68.
138. Wu H, D’Alessio AC, Ito S, Wang Z, Cui K, Zhao K, Sun YE, Zhang Y. 2011a. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev 25: 679–684.
139. Wu H, D’Alessio AC, Ito S, Xia K, Wang Z, Cui K, Zhao K, Sun YE, Zhang Y. 2011b. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473: 389–393.
140. Wu H, Wu X, Shen L, Zhang Y. 2014. Single-base resolution analysis of active DNA demethylation using methylase-assisted bisulfite sequencing. Nat Biotechnol 32: 1231–1240.
141. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y, et al. 2012. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26: 1326–1338.
142. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, et al. 2014. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20: 1472–1478.
143. Xu C, Bian C, Lam R, Dong A, Min J. 2011a. The structural basis for selective binding of non-methylated CpG islands by the CFP1 CXXC domain. Nat Commun 2: 227.
144. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, Ito S, Yang C, Wang P, Xiao M-T, et al. 2011b. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17–30.
145. Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, Zheng L, Zhang H, Huang S, et al. 2011c. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42: 451–464.
146. Xu Y, Xu C, Kato A, Tempel W, Abreu JG, Bian C, Hu Y, Hu D, Zhao B, Cerovina T, et al. 2012. Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell 151: 1200–1213.
147. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, et al. 2012. Effects of TET2 mutations on DNA methylation in chronicmyelomonocytic leukemia. Epigenetics 7: 201–207.
148. Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, et al. 2015. TET2 mutations affect non-CpG Island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia. Cancer Res 75: 2833–2843.
149. Yang H, Liu Y, Bai F, Zhang J-Y, Ma S-H, Liu J, Xu Z-D, Zhu H-G, Ling Z-Q, Ye D, et al. 2013. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32: 663–669.
150. Yardimci H, Zhang Y. 2015. Charting oxidized methylcytosines at base resolution. Nat Struct Mol Biol 22: 656–661.
151. Yin R, Mao S-Q, Zhao B, Chong Z, Yang Y, Zhao C, Zhang D, Huang H, Gao J, Li Z, et al. 2013. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc 135: 10396–10403.
152. Yu M, Hon GC, Szulwach KE, Song C-X, Zhang L, Kim A, Li X, Dai Q, Shen Y, Park B, et al. 2012. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 149: 1368–1380.
153. Yu C, Zhang Y-L, Pan W-W, Li X-M, Wang Z-W, Ge Z-J, Zhou J-J, Cang Y, Tong C, Sun Q-Y, et al. 2013. CRL4 complex regulates mammalian oocyte survival and reprogramming by activation of TET proteins. Science 342: 1518–1521.
154. Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, Shi YG. 2010. TET1 is a DNA-binding protein that modulates DNAmethylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 20: 1390–1393.
155. Zhang L, Lu X, Lu J, Liang H, Dai Q, Xu G-L, Luo C, Jiang H, He C. 2012. Thymine DNA glycosylase specifically recognizes 5- carboxylcytosine-modified DNA. Nat Chem Biol 8: 328–330.
156. Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, et al. 2015. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525: 389–393.
157. Zhao Z, Chen L, Dawlaty MM, Pan F, Weeks O, Zhou Y, Cao Z, Shi H, Wang J, Lin L, et al. 2015. Combined loss of Tet1 and Tet2 promotes B cell, but not myeloid malignancies, in mice. Cell Rep 13: 1692–1704.
158. Zhou T, Xiong J, Wang M, Yang N, Wong J, Zhu B, Xu R-M. 2014. Structural basis for hydroxymethylcytosine recognition by the SRA domain of UHRF2. Mol Cell 54: 879–886.
159. Ziller MJ, Gu H, Müller F, Donaghey J, Tsai LT-Y, Kohlbacher O, De Jager PL, Rosen ED, Bennett DA, Bernstein BE, et al. 2013. Charting a dynamic DNA methylation landscape of the human genome. Nature 500: 477–481.